Oramed (NASDAQ: ORMP) discloses 4.9% beneficial stake in Scilex (SCLX)

Rhea-AI Filing Summary

Scilex Holding Company’s Schedule 13G/A Amendment No. 4 reports that Oramed Pharmaceuticals Inc. beneficially owns 437,510 shares of Scilex common stock, representing 4.9% of the outstanding class. These shares are issuable upon exercise of warrants and conversion of convertible notes that are exercisable within 60 days.

The ownership percentage is calculated using 8,491,267 Scilex common shares outstanding as of December 5, 2025, plus the 437,510 shares underlying Oramed’s instruments. Oramed states the securities were not acquired and are not held for the purpose of changing or influencing control of Scilex.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What ownership stake in Scilex Holding Co (SCLX) does Oramed report in this Schedule 13G/A?

Oramed Pharmaceuticals Inc. reports beneficial ownership of 437,510 shares of Scilex common stock, representing 4.9% of the class. This stake is based on Scilex’s reported 8,491,267 outstanding shares plus Oramed’s warrant and note conversion shares.

How did Oramed’s 4.9% ownership in Scilex (SCLX) common stock arise?

The 4.9% beneficial ownership comes from warrants and convertible notes held by Oramed that are exercisable within 60 days. These instruments are convertible into 437,510 Scilex common shares, which form the entire amount Oramed reports as beneficially owned.

What share count did Scilex (SCLX) report that underlies Oramed’s 4.9% calculation?

The 4.9% figure uses 8,491,267 Scilex common shares outstanding as of December 5, 2025, as reported in a Scilex prospectus filed under Rule 424(b)(3). Oramed then adds its 437,510 issuable shares from warrants and convertible notes to compute its percentage.

Does Oramed’s Schedule 13G/A filing indicate an intent to control Scilex Holding Co (SCLX)?

The filing explicitly states the securities “were not acquired and are not held” for the purpose or effect of changing or influencing control of Scilex. It also notes they are not held in connection with any control-related transaction, other than activities related to specified nomination rules.

What voting and dispositive powers does Oramed report over its Scilex (SCLX) holdings?

Oramed reports sole voting power and sole dispositive power over all 437,510 Scilex shares underlying its warrants and convertible notes. It reports no shared voting or shared dispositive power, indicating exclusive control over how these securities are voted and disposed.

What is the significance of Oramed owning 5 percent or less of Scilex (SCLX) stock?

The filing notes ownership of 5 percent or less of Scilex’s common stock, with Oramed’s interest at 4.9%. Being under the 5% threshold can affect certain regulatory and disclosure requirements, and the Schedule 13G/A documents this sub‑5% beneficial ownership level.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Scilex Holding Co

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

80880W205

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 80880W205

1

Names of Reporting Persons

Oramed Pharmaceuticals Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 437,510.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 437,510.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

437,510.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Scilex Holding Co
(b)	Address of issuer's principal executive offices: 960 San Antonio Road, Palo Alto, CA 94303
Item 2.
(a)	Name of person filing: Oramed Pharmaceuticals Inc. (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: 1185 Avenue of the Americas, Third Floor, New York, NY 10036
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 80880W205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Rows 5 through 9 of the cover page for the Reporting Person and is incorporated herein by reference. The amount beneficially owned is comprised of 437,510 shares of common stock, par value $0.0001 per share ("Common Stock") of Scilex Holding Co (the "Issuer") issuable upon exercise of warrants and conversion of convertible notes held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the Securities and Exchange Commission ("SEC").
(b)	Percent of class: The information required by Item 4(b) is set forth in Row 11 of the cover page for the Reporting Person and is incorporated herein by reference. The percent of class beneficially owned reported in Row 9 of the cover page for the Reporting Person is calculated based on 8,491,267 shares of Common Stock outstanding as of December 5, 2025, as reported by the Issuer in its Prospectus filed pursuant to Rule 424(b)(3) with the SEC on December 29, 2025, plus 437,510 shares of Common Stock issuable upon exercise of warrants and conversion of convertible notes held by the Reporting Person that are exercisable within 60 days of the date on which this Schedule 13G has been filed with the SEC.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 437,510
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 437,510
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Oramed Pharmaceuticals Inc.

Signature:	/s/ Avraham Gabay
Name/Title:	Avraham Gabay, Chief Financial Officer
Date:	02/13/2026